With the approval ofpolatuzumab vedotin(Polivy®; Genentech/Roche),enfortumab vedotin-ejfv(Padcev™; Astellas/Seattle Genetics) and fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo/AstraZeneca), there were more ADCs carrying cytotoxic payloads approved by t...
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgues JM et al (2021) Polatuzumab vedotin in previously untreated...
Several novel antibodies, ADCs and BiTEs are in advanced stages of clinical trials and have been recently recommended by the NCCN guidelines. These include the anti-CD79b ADC polatuzumab vedotin, the CD3-CD20 BiTE mosunetuzumab and the anti-CD47 antibody magrolimab (Hu5F9-G4). Polatuzuma...